In addition, in our unselected cohort, many PGVs are identified in genes such as BRCA1, MSH6, PMS2, and NF1, which are crucial not only for germline follow-up but also for selecting appropriate therapies, particularly immune-based or targeted treatments, as observed in other tumor types. The gene discussed is MSH6; the disease is neoplasm.